Skin Cancer

Melanoma survivor offers help based on her own melanoma experience and reading.

Survivor shares that there is no shame to talk to a therapist about life’s difficulties, especially when those difficulties have included coping with a cancer diagnosis and the ongoing fear of recurrence.

Cancer has a silver lining, too. Breast cancer and melanoma survivor shares hers.

Two-time cancer survivor offers help for fatigue, including fatigue that is months and years out from active treatment

Breast cancer and melanoma survivor comments on downsizing from a cancer survivor's perspective.

Breast cancer survivor approaches the phone with dread with Mom in hospice with breast cancer.

Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.

Diagnosed with desmoplastic melanoma, sportscaster Holly Rowe is working with the Melanoma Research Foundation to teach about the disease.

An immunotherapy has become the first of its kind approved to treat Merkel cell carcinoma, a rare and still mysterious skin cancer.

Creams containing the chemotherapy 5-fluorouracil can be fatal to animals, the FDA warns.

In treating rare advanced skin cancers, individualized therapy is improving outcomes.

A study pairs an IDO inhibitor with PD-1 checkpoint blockade.

Increasingly, immunotherapy drugs for advanced melanoma are being studied in combination.

During and after surgery for skin cancer, a number of strategies can help minimize scarring.

Cancer not only wages war on our bodies, but also our relationships with food. Are cancer-fighting diets really the answer?

Clinical trials are a crucial aspect in deciding therapies for patient populations with high-risk melanoma.

While the summer months are the perfect time for outdoor activities with friends and family, it is crucial to protect yourself from skin cancer.

Promising clinical activity and acceptable safety was shown when the PD-1 inhibitor Keytruda (pembrolizumab) was given with the HDAC inhibitor entinostat for patients with melanoma who were refractory to immune checkpoint inhibitors.

There is hot debate over whether full-body skin exams should be done each year to help in early detection of both non-melanoma and melanoma skin cancers.

Patients with squamous cell carcinoma of the head and neck (SCCHC) and those with melanoma saw some promising activity with the drug combination of epacadostat and Opdivo (nivolumab), according to findings from the phase 1/2 ECHO-204 study presented at the 2017 ASCO Annual Meeting.

Opdivo (nivolumab) plus Yervoy (ipilimumab) demonstrated a response in some patients with melanoma brain metastases, according to a recent study presented at ASCO.

A recent clinical trial showed that psychological intervention can ease patients' anxiety and fear of recurrence.

Researchers found that nearly 75 percent of sunscreen products contain less SPF than labeled, and the Environmental Working Group (EWG) is working to have that changed.

Patients with in immunotherapy-naïve and pretreated patients with advanced melanoma saw a 50 percent overall response rate (ORR) when adding a formulation of the Coxsackievirus A21 (CVA21; CAVATAK®) to Yervoy (ipilimumab) – a combination which was well-tolerated.

A plan for remembering your loved one when times get tough.

Non-invasive imaging devices can help dermatologists examine the skin and a lesion without a biopsy, which requires cutting of the skin.

Since being diagnosed with desmoplastic melanoma in 2016, Holly Rowe has teamed up with the Melanoma Research Foundation to spread awareness of skin cancer.

As we approach summer, a melanoma survivor recovers from her fresh wounds and shares her thoughts.

All is NOT fair in love and war

Immunotherapy showed improved survival benefits for stage 3 and 4 melanoma, but it came at a price of greater toxicity, according to a randomized, double-blind phase 3 study that compared 10 mg/kg Yervoy (ipilimumab) or a lower dose of the anti-CTLA-4 anticlonal antibody.